ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ICOS Icos

0.00
0.00 (0.00%)
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Icos NASDAQ:ICOS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

ICOS to Release Financial Results for 2006 Second Quarter on August 3, 2006

20/07/2006 1:00am

Business Wire


Icos (NASDAQ:ICOS)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Icos Charts.
ICOS Corporation (Nasdaq:ICOS) will announce its 2006 second quarter financial results on Thursday, August 3, 2006, after the market close. At 4:30 p.m. EDT, company management will host a webcast discussion of financial results and related matters, including financial guidance and future plans. Access to the discussion can be obtained as follows. LIVE Access on August 3, 2006, 4:30 p.m. EDT: -- Phone 612-332-1025; Passcode 834085. -- Webcast connection through the ICOS Web site at www.icos.com in the Investor/Events section. REPLAY Access: -- Phone replay accessible from August 3, 2006, 8:00 p.m. EDT, for 24 hours at 320-365-3844, Passcode 834085. -- Webcast replay, available through August 10, 2006, on the ICOS Web site at www.icos.com in the Investor/Events section. Additional information on ICOS, including past press releases, is also available at www.icos.com. About ICOS Corporation ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients. Through Lilly ICOS LLC, ICOS is marketing its first product, Cialis(R) (tadalafil), for the treatment of erectile dysfunction. ICOS is working to develop treatments for serious unmet medical needs such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer and inflammatory diseases. The forward-looking statements contained in this press release represent ICOS' judgment as of the date of this release. ICOS undertakes no obligation to publicly update any forward-looking statements. The biotechnology and pharmaceutical businesses are risky and there can be no assurance that any particular product or product candidate will be a commercial success.

1 Year Icos Chart

1 Year Icos Chart

1 Month Icos Chart

1 Month Icos Chart

Your Recent History

Delayed Upgrade Clock